Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | NOS3 | P29474 | 3/20 | 0.53 |
| ▸ | NOS2 | P35228 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406462 | 1.00 | NOS1 (0.53) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL5387929 | 0.85 | NOS1 (0.57) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL5387924 | 0.85 | NOS1 (0.57) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL6957505 | 0.80 | NPC1 (0.60) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL4399592 | 0.79 | NOS1 (0.50) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL4399594 | 0.79 | NOS1 (0.50) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL6958481 | 0.79 | NOS1 (0.62) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL4400410 | 0.79 | NOS1 (0.49) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL4400407 | 0.79 | NOS1 (0.49) | NOS1NOS3NOS2NPC1RAB9A | |
| SCHEMBL4625735 | 0.78 | MT-CO2 (0.59) | NOS1NOS3NOS2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | claimed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | claimed |
| EP-1115719-A2 | NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-07-18 | — | — | EP | claimed |
| WO-2000017190-A2 | AMIDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-03-30 | — | — | WO | claimed |
| US-7576241-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2009-08-18 | — | — | US | disclosed |
| US-7473779-B2 | Derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-01-06 | — | — | US | disclosed |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | IPSEN PHARMA S.A.S. (FR) | 2006-04-20 | — | — | US | disclosed |
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D' APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) | 2005-11-24 | — | — | US | disclosed |
| US-6653312-B1 | Such as 3-((3-((amino(2-thienyl)methylideneamino)-benzyl)-amino)-N-(1- methyl-2,3-dihydro-1H-indol-5-yl)propanamide; NO-synthase enzyme inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2003-11-25 | — | — | US | disclosed |
| EP-1318149-A1 | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2003-06-11 | — | — | EP | disclosed |
| EP-1115719-A2 | NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000017190-A2 | AMIDINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261269-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | NOS2, NOS1, NOS3 | NOS1 2/4885NOS3 3/4885NOS2 1/4885 |
| US-20060084667-A1 | New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them | ADM2, NUP155, ABCG2 | NOS1 247/4885NOS3 100/4885NOS2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.